Published in Oncogene on June 23, 2005
Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 2.46
Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol (2008) 2.21
Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia (2006) 1.81
Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res (2009) 1.65
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Division of labor by dual feedback regulators controls JAK2/STAT5 signaling over broad ligand range. Mol Syst Biol (2011) 1.45
Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2015) 1.41
Drosophila follicle cells: morphogenesis in an eggshell. Semin Cell Dev Biol (2008) 1.36
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood (2009) 1.16
Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol (2008) 1.16
Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events. PLoS One (2011) 1.15
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci (2008) 1.14
Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res (2008) 1.14
Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care (2011) 1.03
STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res (2011) 0.99
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med (2010) 0.99
The effect of erythropoietin on normal and neoplastic cells. Biologics (2012) 0.98
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol (2015) 0.97
Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene (2011) 0.96
Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest (2014) 0.94
RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. Mol Ther (2011) 0.93
Epigenetic silencing of erythropoietin in human cancers. Genes Cancer (2011) 0.92
Erythropoietin and cancer: the unintended consequences of anemia correction. Front Immunol (2014) 0.91
SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma. Br J Cancer (2014) 0.89
Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget (2013) 0.89
RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol (2009) 0.89
Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci (2010) 0.89
Gene expression profile changes correlated with lymph node metastasis in oral squamous cell carcinoma. Odontology (2008) 0.87
Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma. BMC Cancer (2012) 0.85
HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal (2014) 0.84
Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun (2009) 0.84
Epoetin beta for the treatment of chemotherapy-induced anemia: an update. Onco Targets Ther (2015) 0.83
Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro. BMC Res Notes (2011) 0.82
Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma. Exp Ther Med (2012) 0.82
Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis. Int J Clin Exp Pathol (2015) 0.81
Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2. Am J Physiol Lung Cell Mol Physiol (2010) 0.81
Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int J Oncol (2011) 0.80
Layered signaling regulatory networks analysis of gene expression involved in malignant tumorigenesis of non-resolving ulcerative colitis via integration of cross-study microarray profiles. PLoS One (2013) 0.80
Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues. PLoS One (2015) 0.79
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer (2010) 0.79
Functional significance of erythropoietin receptor on tumor cells. World J Gastroenterol (2006) 0.78
Paired Box 5 Methylation Detection by Droplet Digital PCR for Ultra-Sensitive Deep Surgical Margins Analysis of Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila) (2015) 0.78
Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma. BMC Cancer (2014) 0.77
Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice. Mol Ther (2013) 0.77
Mining metastasis related genes by primary-secondary tumor comparisons from large-scale databases. BMC Bioinformatics (2009) 0.75
Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. Cell Death Dis (2016) 0.75
Characterization of RNA editome in primary and metastatic lung adenocarcinomas. Oncotarget (2017) 0.75
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. Proc Natl Acad Sci U S A (2006) 7.48
Head and neck cancer. Lancet (2008) 6.33
Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 3.67
Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin Chem (2005) 3.42
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol (2007) 2.57
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Cutting to the chase: calpain proteases in cell motility. Trends Cell Biol (2002) 2.38
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A (2003) 2.35
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer (2010) 2.31
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother (2009) 2.25
Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst (2006) 2.21
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer (2006) 2.16
Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg (2006) 2.12
Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev (2012) 2.08
STAT-mediated EGFR signaling in cancer. J Cell Biochem (2007) 2.05
Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg (2003) 2.04
Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells (2007) 2.03
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
Glu-Leu-Arg-negative CXC chemokine interferon gamma inducible protein-9 as a mediator of epidermal-dermal communication during wound repair. J Invest Dermatol (2003) 1.89
SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res (2004) 1.88
Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem (2003) 1.88
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene (2005) 1.78
Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res (2005) 1.73
IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J Immunol (2010) 1.69
STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ (2002) 1.69
Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A (2006) 1.68
Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg (2009) 1.68
Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells (2005) 1.66
Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. Mol Cell Biol (2002) 1.64
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res (2006) 1.61
Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods (2004) 1.59
The impact of health insurance status on the survival of patients with head and neck cancer. Cancer (2010) 1.58
Lsh is involved in de novo methylation of DNA. EMBO J (2006) 1.57
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid (2012) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C delta-dependent pathway. J Biol Chem (2004) 1.55
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci (2008) 1.50
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer (2006) 1.49
Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg (2007) 1.45
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys (2006) 1.42
Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. J Biol Chem (2004) 1.41
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA (2007) 1.41
Comparison of surgical techniques for early-stage thymoma: feasibility of minimally invasive thymectomy and comparison with open resection. J Thorac Cardiovasc Surg (2011) 1.41
EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci (2007) 1.40
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol (2010) 1.40
Bile exposure inhibits expression of squamous differentiation genes in human esophageal epithelial cells. Ann Surg (2012) 1.40
Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck (2011) 1.40
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.39
Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen (2004) 1.39
Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther (2010) 1.39
IP-10 induces dissociation of newly formed blood vessels. J Cell Sci (2009) 1.38
Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev (2007) 1.38
Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor. Am J Pathol (2007) 1.38
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Partial mesenchymal to epithelial reverting transition in breast and prostate cancer metastases. Cancer Microenviron (2011) 1.37
The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas. Cancer Cell (2013) 1.36
Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res (2006) 1.35
Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-calpain. Mol Cell Biol (2005) 1.35